Mixed Chimeric Transplantation for Primary Amyloidosis
This study has been withdrawn prior to enrollment.
(Closed, never started.)
Information provided by:
First received: September 13, 2005
Last updated: October 5, 2007
Last verified: October 2007
To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.
Procedure: autologous followed by nonmyeloablative allogeneic transplant
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Mixed Chimeric Transplantation for Primary Amyloidosis|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Stanford University:
Primary Outcome Measures:
- Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.
Secondary Outcome Measures:
- Toxicity of therapy
- Changes in marrow and serum abnormalities
- Improvement in end-organ function.
|Study Start Date:||December 2000|
|Estimated Study Completion Date:||September 2006|
Contacts and Locations